EyePoint Pharmaceuticals has announced positive Phase 2 results for its investigational sustained delivery maintenance treatment, EYP-1901, in patients with wet age-related macular degeneration (wet AMD), according to a company press release.
The trial demonstrated a statistically non-inferior change in best corrected visual acuity (BCVA) compared to the aflibercept control, with a difference of only -0.3 and -0.4 letters for the 2 mg and 3 mg doses, respectively, at the blended 6-month endpoint.
EYP-1901 also exhibited a positive safety profile, with no treatment-related serious adverse events, and achieved key secondary endpoints, including a significant reduction in treatment burden and a high proportion of eyes remaining supplement-free up to six months.
“We are incredibly pleased by these highly positive Phase 2 results which underscore EYP-1901’s potential as a paradigm-altering maintenance treatment for patients with wet AMD, with a positive safety profile. Since EYP-1901 achieved statistical non-inferiority to the aflibercept control in this trial there is potential for meaningfully lower sized and lower cost pivotal Phase 3 trials,” said Jay S. Duker, MD, President and Chief Executive Officer of EyePoint Pharmaceuticals. “I would like to thank the patients and the investigators who participated in the DAVIO 2 trial as well as our employees who helped advance us to this important milestone.”
Read the full press release here.
Related Content
